Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5957 Target Snapshot

5'-nucleotidase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,236Compounds
173Assays
0Approved Drugs
1,961.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

5'-nucleotidase shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P21589. Start with non-small cell lung carcinoma, then reuse UniProt P21589 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with non-small cell lung carcinoma, then reuse UniProt P21589 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
non-small cell lung carcinoma

5'-nucleotidase shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include OLECLUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5'-nucleotidase as ChEMBL target CHEMBL5957, mapped to UniProt P21589. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5'-nucleotidase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5957
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21589
5'-nucleotidase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5'-nucleotidase is the right protein anchor across sources, using UniProt P21589 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why non-small cell lung carcinoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name5'-nucleotidase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP21589
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5'-nucleotidase
UniProt AccessionP21589
Component TypeProtein
Sequence Length574 aa

5'-nucleotidase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 5'-nucleotidase, mapped to UniProt P21589. Sequence length is 574 aa.

Mapped IDP21589
Review name5'-nucleotidase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

5'-nucleotidase shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOLECLUMAB
Clinical signal Phase II
colorectal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugOLECLUMAB
Clinical signal Phase II
colorectal carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOLECLUMAB
Clinical signal Phase II
pancreatic carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOLECLUMAB
Clinical signal Phase II
pancreatic ductal adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOLECLUMAB
Clinical signal Phase II
prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugOLECLUMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include OLECLUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasenon-small cell lung carcinoma
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase III
4
Phase II
4
Phase I
2
Phase 0.5
Assay Mix

Activity Type Distribution

IC501,812.0
KI140.0
EC508.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4761506 11.0 IC50 0.01 Preclinical
CHEMBL4471306 10.96 IC50 0.011 Clinical
CHEMBL5431118 10.89 IC50 0.013 Preclinical
CHEMBL4749428 10.57 IC50 0.027 Preclinical
CHEMBL4776758 10.55 IC50 0.028 Preclinical
CHEMBL4746184 10.51 IC50 0.031 Preclinical
CHEMBL4740465 10.51 IC50 0.031 Preclinical
CHEMBL4797225 10.49 IC50 0.032 Preclinical
CHEMBL5423436 10.42 Ki 0.038 Preclinical
CHEMBL4743437 10.35 IC50 0.045 Preclinical
Distribution

pChEMBL Value Distribution

101
5.0
178
5.5
248
6.0
272
6.5
154
7.0
92
7.5
91
8.0
93
8.5
74
9.0
49
9.5
pChEMBL
Assay Landscape

Assay Landscape

173
Total Assays
914
Tested Compounds
1
Assay Types
Binding — 173 assays, 914 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 78 290 7.5
single protein format 77 502 6.8
tissue-based format 7 4 10.4
cell-free format 6 22 8.2
assay format 5 96 6.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine